- The SoInAb™ antibody platform reached PCC, expanding the antibody drug candidate pool.
- The SoInNuc™ Intelligent Nucleic Acid Drug Development Platform was launched.
- The SoInZyme™ Enzyme Engineering Platform was launched.
- Strategic partnerships were established with multiple pharmaceutical companies to advance the translational deployment of small nucleic acid and enzyme optimization technologies.
- The tendon stem cell drug candidate completed national filing.
- The Longevity Clinic was launched to explore an integrated "R&D–Production–Application" model.
- National High-Tech Enterprise status is under review.
- Class II medical device approval was received.
2026
- An in-house AI computing center was built to support platform R&D.
- The tendon stem cell (TSPC) IIT clinical trial was approved at the Second Affiliated Hospital of Zhejiang University.
- The PLLA microsphere facial injectable Class III medical device clinical trial was approved.
- Investments were made in Huadao Biotechnology, Zhitang Technology, and Shanwan Biotechnology, expanding into cell and gene therapy.
2025
- An AI-driven de novo antibody discovery platform and R&D system were established.
- An AI-assisted biomaterial design platform was developed.
- APRBIO Biotechnology was founded, focusing on advanced biomaterials and medical aesthetics & wellness.
- VitaSalus Intelligent Technology was incubated, focusing on neuromodulation and electrical stimulation R&D.
- The company was named a Zhejiang Provincial Science & Technology SME.
2024
- An AI-assisted musculoskeletal repair platform was established.
- CoJump Sports Medicine and Starlight Aesthetics Center were incubated.
- A leading sports medicine rehabilitation facility in the province was completed.
- An industrial portfolio covering sports medicine, regenerative medicine, and medical aesthetics was built.
2023
- SUNRAY Biotechnology was established, committed to data intelligence-driven biopharmaceutical innovation.
2022
- The SoInAb™ antibody platform reached PCC, expanding the antibody drug candidate pool.
- The SoInNuc™ Intelligent Nucleic Acid Drug Development Platform was launched.
- The SoInZyme™ Enzyme Engineering Platform was launched.
- Strategic partnerships were established with multiple pharmaceutical companies to advance the translational deployment of small nucleic acid and enzyme optimization technologies.
- The tendon stem cell drug candidate completed national filing.
- The Longevity Clinic was launched to explore an integrated "R&D–Production–Application" model.
- National High-Tech Enterprise status is under review.
- Class II medical device approval was received.
2026
- An in-house AI computing center was built to support platform R&D.
- The tendon stem cell (TSPC) IIT clinical trial was approved at the Second Affiliated Hospital of Zhejiang University.
- The PLLA microsphere facial injectable Class III medical device clinical trial was approved.
- Investments were made in Huadao Biotechnology, Zhitang Technology, and Shanwan Biotechnology, expanding into cell and gene therapy.
2025
- An AI-driven de novo antibody discovery platform and R&D system were established.
- An AI-assisted biomaterial design platform was developed.
- APRBIO Biotechnology was founded, focusing on advanced biomaterials and medical aesthetics & wellness.
- VitaSalus Intelligent Technology was incubated, focusing on neuromodulation and electrical stimulation R&D.
- The company was named a Zhejiang Provincial Science & Technology SME.
2024
- An AI-assisted musculoskeletal repair platform was established.
- CoJump Sports Medicine and Starlight Aesthetics Center were incubated.
- A leading sports medicine rehabilitation facility in the province was completed.
- An industrial portfolio covering sports medicine, regenerative medicine, and medical aesthetics was built.
2023
- SUNRAY Biotechnology was established, committed to data intelligence-driven biopharmaceutical innovation.
2022
